Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Novo Nordisk A/S hisse başına yıllık % {var1} temettüye sahiptir ve % {var2} oranında bir getiri sunmaktadır. Temettü altı ayda bir ödenmektedir ve son temettü hariç tarihi Aug 18, 2025 tarihindedir.
Dividend Yield
Yıllık Dividende
Özsermaye Tarihi
0.00%
$1.73
Aug 18, 2025
Ödeme Sıklığı
Ödeme Oranı
Altı ayda bir
0.00%
Dividend History
Özsermaye Tarihi
Nakit Tutarı
Kayıt Tarihi
Ödeme Tarihi
Aug 18, 2025
$0.5843
Aug 18, 2025
Aug 26, 2025
Mar 31, 2025
$1.1426
Mar 31, 2025
Apr 8, 2025
Aug 16, 2024
$0.5169
Aug 16, 2024
Aug 26, 2024
Mar 22, 2024
$0.9293
Mar 25, 2024
Apr 2, 2024
Aug 18, 2023
$0.4382
Aug 21, 2023
Aug 29, 2023
Mar 24, 2023
$0.5903
Mar 27, 2023
Apr 4, 2023
Dividend Grafikleri
NVO Kâr Payları
NVO Dividend Growth (Yıllık Üstünlük)
Follow-Up Questions
Novo Nordisk A/S'in şu anki temettü ödemesi ve yıllık temettüsü nedir?